Clinical

Articles for Clinical

A new report released by the American Cancer Society indicates that while the cancer-related death rate was higher among blacks than in whites in 2014, the racial gap could reduce as minority patients increasingly gain access to insurance and subsequent healthcare.
The abortion rate in the United States hit a historic low in 2014 with 2 likely contributing factors: improved access to contraceptives and increased restrictions to abortion services.
Despite the complexities associated with treating older patients diagnosed with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), patients in the RESONATE-2 trial continue to present a favorable response to single-agent ibrutinib at a follow-up of 29 months.
The results showed that obinutuzumab-based immunochemotherapy and maintenance improved progression-free survival in treatment-naïve patients with follicular lymphoma.
A study in a mouse model found that mice receiving chimeric antigen receptor (CAR)-T immunotherapy plus ibrutinib demonstrated longer overall survival and reduced cytokine production than the mice not treated with ibrutinib.
The improved expansion of chimeric antigen receptor (CAR) T-cells indicates a deeper clinical response.
A novel, simplified cost-value analysis tool was created to better differentiate the value of anticancer agents and further characterize the expected survival benefit of all patients.
The trial, evaluating the programmed death ligand-1 inhibitor durvalumab, alone or in combination with tremelimumab, versus platinum-based chemotherapy, has refined its endpoints to include overall survival (OS) along with progression-free survival.
Compendia
COPD Compendium
Diabetes Compendium
MACRA Compendium
Oncology Compendium
Rare Disease Compendium
Reimbursement Compendium
Know Your News
HF Compendium
$AD300x250BB$
$vacMongoViewPlus$